secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2022-07-21T23:59:59+00:00
Accession:  0001516551-22-000018
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience extends merger Outside Date with Emerald Health to Oct 15, 2022; adjusts meeting timeline for SEC review
--------------------------------------------------------------------------------

- Outside Date extended to October 15, 2022; auto-extends to Nov 15 if SEC reviews proxy statement.
- Shareholder meeting must be held by Oct 4 (no SEC review), Nov 4 (SEC review), or Nov 14 (amendments required).
- Second amendment to Arrangement Agreement dated May 11, 2022; parties may further extend Outside Date by 45 days.
- Extension conditioned on satisfaction of certain closing conditions and regulatory approvals not yet obtained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655122000018/0001516551-22-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655122000018/skye-20220715.htm
  HTML page:      https://secwatch.observer/filing/0001516551-22-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer